Oral GLP-1 treatments / working resource

Study reading worksheet

Separate a reported result from the question the study was designed to answer.

Start with the product-specific question

Peptide tablets versus small-molecule GLP-1 medicines

The oral-treatment specialist, with molecule and formulation distinctions. What should I know about peptide tablets versus small-molecule glp-1 medicines?

The June 2026 US Wegovy label includes oral tablets for long-term adult weight reduction and cardiovascular risk reduction in specified adults, with diet and physical activity.
Read the original record ↗

Open the Oral GLP-1s library ↗

Write the question before the result.

A Oral GLP-1s headline may describe an animal experiment, an uncontrolled observation or a randomized human trial. Those designs answer different questions. Complete the record before deciding whether a result applies to a product.

Document title and original URLExact molecule, formulation and route studiedStudy design and number of participants or samplesPopulation, condition and inclusion criteriaComparison or control groupPrimary endpoint and follow-up period

Keep the result attached to its boundary.

Actual result, units and uncertainty intervalWhich analysis or estimand produced this number?Was this the primary endpoint or a subgroup finding?Adverse events and missing or incomplete follow-upFunding, conflicts, correction or later publicationWhat does this study leave unanswered for this product?

When there is no human comparison group or no relevant clinical endpoint, record that explicitly. A mechanism, biomarker or plausible explanation does not become a demonstrated patient benefit.

These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.

Explore all six resources ↗